Cited by 998Barrier Structure and Function StudiesNeurological Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

The role of brain vasculature in neurodegenerative disorders

Open access
Sweeney, Melanie D., Kisler, Kassandra, Montagne, Axel, Toga, Arthur W., Zlokovic, Berislav V.·2018·Nature Neuroscience

Abstract

Adequate supply of blood and structural and functional integrity of blood vessels are key to normal brain functioning. On the other hand, cerebral blood flow shortfalls and blood-brain barrier dysfunction are early findings in neurodegenerative disorders in humans and animal models. Here we first examine molecular definition of cerebral blood vessels, as well as pathways regulating cerebral blood flow and blood-brain barrier integrity. Then we examine the role of cerebral blood flow and blood-brain barrier in the pathogenesis of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis. We focus on Alzheimer's disease as a platform of our analysis because more is known about neurovascular dysfunction in this disease than in other neurodegenerative disorders. Finally, we propose a hypothetical model of Alzheimer's disease biomarkers to include brain vasculature as a factor contributing to the disease onset and progression, and we suggest a common pathway linking brain vascular contributions to neurodegeneration in multiple neurodegenerative disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41593-018-0234-x

Cites

151 of 151 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Binding of AGEs and amyloid beta to RAGE causes additional oxidative stress that contributes to neuronal death and vascular dementia in Alzheimer disease.

    “AGE and Aβ binding to RAGE leads to further oxidative stress that contributes to neuronal death and vascular dementia in AD45–48.”

    From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [48]

    The Alzheimer’s disease blood–brain barrier sections (page unavailable) identify RAGE as an Aβ influx transporter and report increased RAGE-mediated Aβ influx in AD models. They do not state that AGE and Aβ binding to RAGE causes oxidative stress leading to neuronal death and vascular dementia. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Glycation may slow the conversion of amyloid beta into fibrils, keeping it longer in toxic oligomeric forms.

    “Glycation may slow the conversion of Aβ to fibrils, keeping them longer in the toxic oligomeric forms48.”

    From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [48]

    The Blood-brain barrier in Alzheimer’s disease sections discuss Aβ transport and accumulation, including a receptor for advanced glycation endproducts, but do not address glycation of Aβ itself. Searches for slowed fibril formation and prolonged toxic oligomeric forms found no passage supporting that mechanism; page numbers were not available in our copy. (LLM, conf=0.74)

    Experimental — accuracy not yet measured
  • Existing cerebrovascular-function-modulating therapeutics eventually failed to alleviate cognitive deficits in AD patients and AD model mice.

    “However, these efforts eventually failed to alleviate the cognitive deficits in AD patients and AD model mice,[ 7 , 8 ]”

    From Multifunctional Nanostructure RAP‐RL Rescues Alzheimer's Cognitive Deficits through Remodeling the Neurovascular Unit (2021) · cites this paper as [7]

    The ‘Cerebral blood flow in Alzheimer’s disease > Animal studies’ section says that counteracting Aβ effects after vascular deposition did not reverse neurovascular dysfunction in an APP mouse model. It does not report whether cerebrovascular-function-modulating therapeutics failed to alleviate cognitive deficits in those mice or in AD patients; searches for treatment failures and cognitive outcomes found no such passage in our copy. (LLM, conf=0.74)

    Experimental — accuracy not yet measured
  • BBB dysfunction is an early and independent contributor to AD pathogenesis, involving pericyte loss, tight-junction breakdown, and increased vascular permeability.

    “BBB dysfunction is now recognized as an early and independent contributor to AD pathogenesis, involving pericyte loss, tight-junction breakdown, and increased vascular permeability (Montagne et al., 2017; Sweeney et al., 2018).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

2 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sweeney, M. D., Kisler, K., Montagne, A., Toga, A. W., & Zlokovic, B. V.
Affiliations
University of Southern California (US)
Venue
Nature Neuroscience
Published
2018-09-24
Volume
21
Issue
10
Pages
1318-1331
ISSN
  • 1097-6256 (ISSN-L)
  • 1546-1726
OpenAlex
W2890224686
Cited by
998
References
151
Citations by year
2026: 113 · 2025: 154 · 2024: 152 · 2023: 137 · 2022: 117 · 2021: 142 · 2020: 116 · 2019: 64 · 2018: 3
FWCI
7.68
Type
journal article
Language
en
Open access
Locations
  • Nature Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Fondation Leducq
  • National Institutes of Health
  • National Institute on Aging (R01AG023084, R01AG039452, P50AG005142, RF1AG039452, P01AG052350)
  • National Institute of Neurological Disorders and Stroke (R01NS100459, R01NS090904, R01NS034467)
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
cerebral vasculature, neurodegenerative diseases, cerebral blood flow, blood-brain barrier dysfunction, neurovascular dysfunction, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease biomarkers, vascular integrity
MeSH terms
Animals, Blood Vessels, Brain, Humans, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review